Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
Back
Updates on HER2-Directed ADCs Across Solid Tumors
Vijayakrishna Gadi, MD, PhD, sets the stage for a discussion around HER2-directed ADCs in the solid tumor space.
Updates on HER2-Directed ADCs Across Solid Tumors
Episodes
All
All
Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.
Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.
Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.
EP. 5: ADCs Targeting GI Cancers
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
EP. 6: ADCs Targeting HER2+ Lung Cancer
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.
EP. 7: Impact of ADCs on Brain Metastases
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.
EP. 8: ADCs Targeting HER2+ GU Cancers
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers
EP. 9: Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.
EP. 10: The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.
EP. 11: Managing ILD and Pneumonitis Risk From ADCs
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.
EP. 12: Managing Toxicities in Short- and Long-Term Treatment with ADCs
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.
A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.
Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.
Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.
Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.
Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.
Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.
Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
Sequencing, Access, and Eligibility Drive CAR T-Cell Therapy Decisions in Early Relapse Myeloma
3
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
4
DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer
5